Prasugrel reduces ischaemic infarct volume and ameliorates neurological deficits in a non-human primate model of middle cerebral artery thrombosis

Thrombosis Research

Volumn 136, Issue 6, 2015, Pages 1224-1230

  Tomizawa, Atsuyuki ^a   Ohno, Kousaku ^a   Jakubowski, Joseph A ^b   Mizuno, Makoto ^a   Sugidachi, Atsuhiro ^a  

^a DAIICHI SANKYO CO   (Japan)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Ischemic stroke; Non human primate; P2Y12 antagonist; Platelet; Prasugrel

Indexed keywords

CLOPIDOGREL; PRASUGREL; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; BRAIN BLOOD FLOW; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; MACACA FASCICULARIS; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MONOTHERAPY; NEUROLOGIC DISEASE; NONHUMAN; PRIMATE MODEL; PRIORITY JOURNAL; REPEATED DRUG DOSE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; ANIMAL; BLEEDING; BLOOD PRESSURE; CHEMISTRY; DISEASE MODEL; HAPLORHINI; INFARCTION, MIDDLE CEREBRAL ARTERY; MYOCARDIAL ISCHEMIA; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; STROKE; THROMBOSIS; TIME FACTOR;

ADENOSINE DIPHOSPHATE; ADMINISTRATION, ORAL; ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HAPLORHINI; HEMORRHAGE; INFARCTION, MIDDLE CEREBRAL ARTERY; MACACA FASCICULARIS; MALE; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; STROKE; THROMBOSIS; TIME FACTORS;

EID: 84949321627     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.09.013     Document Type: Article

References (34)

1. V.L. Roger, A.S. Go, D.M. Lloyd-Jones, R.J. Adams, J.D. Berry, T.M. Brown, and et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association Circulation 123 2011 e18 209
2. N. Nagai, B.Q. Zhao, Y. Suzuki, H. Ihara, T. Urano, and K. Umemura Tissue-type plasminogen activator has paradoxical roles in focal cerebral ischemic injury by thrombotic middle cerebral artery occlusion with mild or severe photochemical damage in mice J. Cereb. Blood Flow Metab. 22 2002 648 651
3. M. Maeda, Y. Furuichi, T. Noto, N. Matsuoka, S. Mutoh, and Y. Yoneda Tacrolimus (FK506) suppresses rt-PA-induced hemorrhagic transformation in a rat thrombotic ischemia stroke model Brain Res. 1254 2009 99 108
4. A. Moriguchi, M. Maeda, K. Mihara, T. Aoki, N. Matsuoka, and S. Mutoh FK419, a novel non peptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban J. Cereb. Blood Flow Metab. 25 2005 75 86
5. B.Q. Zhao, Y. Suzuki, K. Kondo, K. Kawano, Y. Ikeda, and K. Umemura A novel MCA occlusion model of photothrombotic ischemia with cyclic flow reductions: development of cerebral hemorrhage induced by heparin Brain Res. Protocol. 9 2002 85 92
6. S. Ikeda, K. Harada, A. Ohwatashi, Y. Kamikawa, and A. Yoshida A new non-human primate model of photochemically induced cerebral infarction PLoS ONE 8 3 2013 e60037
7. H. Sawada, N. Nishimura, E. Suzuki, J. Zhuang, K. Hasegawa, H. Takamatsu, and et al. SMTP-7, a novel small-molecule thrombolytic for ischemic stroke: a study in rodents and primates J. Cereb. Blood Flow Metab. 34 2014 235 241
8. S. Kaku, K. Umemura, A. Mizuno, S. Yano, K. Suzuki, T. Kawasaki, and et al. Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis Eur. J. Pharmacol. 345 1998 185 192
9. M. Maeda, A. Moriguchi, K. Mihara, T. Aoki, H. Takamatsu, N. Matsuoka, and et al. FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator J. Cereb. Blood Flow Metab. 25 2005 108 118
10. Y. Furuichi, M. Maeda, N. Matsuoka, S. Mutoh, and T. Yanagihara Therapeutic time window of tacrolimus (FK506) in a nonhuman primate stroke model: comparison with tissue plasminogen activator Exp. Neurol. 204 2007 138 146
11. M. Gent, J.A. Blakely, J.D. Easton, D.J. Ellis, V.C. Hachinski, J.W. Harbison, and et al. The Canadian American ticlopidine study (CATS) in thromboembolic stroke Lancet 1 1989 1215 1220
12. C.A.P.R.I.E. Steering Committee A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348 1996 1329 1339
13. Y. Fukuuchi, H. Tohgi, T. Okudera, Y. Ikeda, Y. Miyanaga, S. Uchiyama, and et al. A randomized, double-blind study comparing the safety and efficacy of clopidogrel versus ticlopidine in Japanese patients with noncardioembolic cerebral infarction Cerebrovasc. Dis. 25 2008 40 49
14. R.L. Sacco, H.C. Diener, S. Yusuf, D. Cotton, S. Ounpuu, W.A. Lawton, and et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke N. Engl. J. Med. 359 2008 1238 1251
15. H. Caplain, and R. Cariou Long-term activity of clopidogrel: a three-month appraisal in healthy volunteers Semin. Thromb. Hemost. 25 Suppl. 2 1999 S21 S24
16. J.J. Thebault, G. Kieffer, G.D. Lowe, W.S. Nimmo, and R. Cariou Repeated-dose pharmacodynamics of clopidogrel in healthy subjects Semin. Thromb. Hemost. 25 Suppl. 2 1999 S9 14
17. T.R. Rao, P.R. Usha, M.U. Naidu, J.A. Gogtay, and M. Meena Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures Curr. Ther. Res. Clin. Exp. 64 2003 685 696
18. 12 inhibitor, compared with clopidogrel in healthy humans Br. J. Clin. Pharmacol. 63 2007 421 430
19. V.L. Serebruany, S.R. Steinhubl, P.B. Berger, A.I. Malinin, D.L. Bhatt, and E.J. Topol Variability in platelet responsiveness to clopidogrel among 544 individuals J. Am. Coll. Cardiol. 45 2005 246 251
20. C. Goh, L. Churilov, P. Mitchell, R. Dowling, and B. Yan Clopidogrel hyper-response and bleeding risk in neurointerventional procedures AJNR Am. J. Neuroradiol. 34 4 2013 721 726
21. 12 receptor antagonist activity Semin. Thromb. Hemost. 31 2005 184 194
22. J.A. Jakubowski, K.J. Winters, H. Naganuma, and L. Wallentin Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile Cardiovasc. Drug. Rev. 25 2007 357 374
23. P.P. Dobesh Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor Pharmacotherapy 29 2009 1089 1102
24. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, S. Gottlieb, and et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N. Engl. J. Med. 357 2007 2001 2015
25. A.D. Michelson, A.L. Frelinger 3rd, E. Braunwald, W.E. Downey, D.J. Angiolillo, N.P. Xenopoulos, and et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial Eur. Heart J. 30 2009 1753 1763
26. T. Kimura, T. Isshiki, H. Ogawa, H. Yokoi, T. Yamaguchi, and Y. Ikeda Randomized, double-blind, dose-finding, phase II study of prasugrel in Japanese patients undergoing elective percutaneous coronary intervention J. Atheroscler. Thromb. 22 2015 557 569
27. S. Saito, T. Isshiki, T. Kimura, H. Ogawa, H. Yokoi, S. Nanto, and et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study Circ. J. 78 2014 1684 1692
28. 12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention: phase III, randomized, double-blind study Circ. J. 78 2014 2926 2934
29. A. Tomizawa, K. Ohno, J.A. Jakubowski, M. Mizuno, and A. Sugidachi Comparison of antiplatelet effects of prasugrel and ticagrelor on cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation Thromb. Haemost. 110 2013 769 776
30. M. Maeda, H. Takamatsu, Y. Furuichi, A. Noda, Y. Awaga, M. Tatsumi, and et al. Characterization of a novel thrombotic middle cerebral artery occlusion model in monkeys that exhibits progressive hypoperfusion and robust cortical infarction J. Neurosci. Methods 146 2005 106 115
31. G. Kito, A. Nishimura, T. Susumu, R. Nagata, Y. Kuge, C. Yokota, and et al. Experimental thromboembolic stroke in cynomolgus monkey J. Neurosci. Methods 105 2001 45 53
32. J.T. Brandt, S.L. Close, S.J. Iturria, C.D. Payne, N.A. Farid, C.S. Ernest 2nd, and et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J. Thromb. Haemost. 5 2007 2429 2436
33. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, J.T. Brandt, and et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 2009 2553 2560
34. S.D. Wiviott, N. Desai, S.A. Murphy, G. Musumeci, M. Ragosta, E.M. Antman, and et al. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies Am. J. Cardiol. 108 2011 905 911